HANSOH PHARMA Shares Surge on New Drug Application Acceptance

Stock News06-05

Shares of HANSOH PHARMA (HKEX: 03692) opened notably higher, gaining over 2%. At the time of writing, the stock is up 2.08%, trading at HK$30.42 with a turnover of HK$16.4 million.

The upward movement follows a company announcement. On June 3, 2026, the New Drug Application (NDA) for its innovative drug, Olaipetide Injection, was officially accepted for review by China's National Medical Products Administration (NMPA). This treatment is intended for the long-term management of body weight in adults who are overweight or obese.

The drug, Olaipetide, is a novel once-weekly dual agonist targeting both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. It is an internally developed product from the company's research pipeline.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1122076064?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-05 09:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1122076064","market":"nz","top_or_hot":-1,"title":"HANSOH PHARMA Shares Surge on New Drug Application Acceptance","media":"Stock News","content":"<p>Shares of <b>HANSOH PHARMA</b> (<b>HKEX: 03692</b>) opened notably higher, gaining over 2%. At the time of writing, the stock is up 2.08%, trading at HK$30.42 with a turnover of HK$16.4 million.<br><br>The upward movement follows a company announcement. On June 3, 2026, the New Drug Application (NDA) for its innovative drug, Olaipetide Injection, was officially accepted for review by China's National Medical Products Administration (NMPA). This treatment is intended for the long-term management of body weight in adults who are overweight or obese.<br><br>The drug, Olaipetide, is a novel once-weekly dual agonist targeting both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. It is an internally developed product from the company's research pipeline.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HANSOH PHARMA Shares Surge on New Drug Application Acceptance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHANSOH PHARMA Shares Surge on New Drug Application Acceptance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-06-05 09:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of <b>HANSOH PHARMA</b> (<b>HKEX: 03692</b>) opened notably higher, gaining over 2%. At the time of writing, the stock is up 2.08%, trading at HK$30.42 with a turnover of HK$16.4 million.<br><br>The upward movement follows a company announcement. On June 3, 2026, the New Drug Application (NDA) for its innovative drug, Olaipetide Injection, was officially accepted for review by China's National Medical Products Administration (NMPA). This treatment is intended for the long-term management of body weight in adults who are overweight or obese.<br><br>The drug, Olaipetide, is a novel once-weekly dual agonist targeting both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. It is an internally developed product from the company's research pipeline.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物医药B类股","start_time":0,"source_url":"","article_id":"1122076064","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1122076064","pubTimestamp":1780622898,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Shares of HANSOH PHARMA (HKEX: 03692) opened notably higher, gaining over 2%. At the time of writing, the stock is up 2.08%, trading at HK$30.42 with a turnover of HK$16.4 million.The upward movement...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159992":"创新药","BK1574":"生物医药B类股","06978":"永泰生物-B","BK1191":"制药","03692":"翰森制药","BK1583":"高瓴概念","BK1161":"生物科技","BK1589":"北水核心资产","VXUS":"国际股票ETF-Vanguard","BK4588":"碎股","BK4585":"ETF&股票定投概念"},"translate_title":"翰森制药股价因新药申请受理而飙升","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159992":1,"03692":1,"06978":1,"VXUS":1},"content_text":"Shares of HANSOH PHARMA (HKEX: 03692) opened notably higher, gaining over 2%. At the time of writing, the stock is up 2.08%, trading at HK$30.42 with a turnover of HK$16.4 million.The upward movement follows a company announcement. On June 3, 2026, the New Drug Application (NDA) for its innovative drug, Olaipetide Injection, was officially accepted for review by China's National Medical Products Administration (NMPA). This treatment is intended for the long-term management of body weight in adults who are overweight or obese.The drug, Olaipetide, is a novel once-weekly dual agonist targeting both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. It is an internally developed product from the company's research pipeline.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1122076064","isCrawlerRequest":true}